Bristol Myers Squibb’s (BMY) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Bristol Myers Squibb (NYSE:BMY) in a report published on Monday morning,Benzinga reports. They currently have a $54.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on BMY. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. HSBC boosted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, Bank of America lowered their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Up 2.7%

Shares of NYSE BMY traded up $1.56 during mid-day trading on Monday, reaching $58.26. 1,001,459 shares of the company’s stock traded hands, compared to its average volume of 12,364,346. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The stock has a market cap of $118.96 billion, a P/E ratio of 16.34, a PEG ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The business has a 50-day simple moving average of $56.90 and a 200 day simple moving average of $57.51.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the company posted $1.80 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts expect that Bristol Myers Squibb will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently modified their holdings of BMY. waypoint wealth counsel purchased a new position in Bristol Myers Squibb during the fourth quarter valued at $1,194,000. Life Cycle Investment Partners Ltd purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $34,406,000. Axxcess Wealth Management LLC boosted its holdings in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after buying an additional 21,196 shares during the period. Daytona Street Capital LLC purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $1,362,000. Finally, Pensionfund Sabic purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $1,845,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.